Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) EVP Suzanne Sawochka Hooper sold 4,580 shares of Jazz Pharmaceuticals PLC stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $160.00, for a total value of $732,800.00. Following the sale, the executive vice president now directly owns 32,322 shares in the company, valued at $5,171,520. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Suzanne Sawochka Hooper also recently made the following trade(s):

  • On Friday, June 23rd, Suzanne Sawochka Hooper sold 420 shares of Jazz Pharmaceuticals PLC stock. The shares were sold at an average price of $160.00, for a total transaction of $67,200.00.
  • On Tuesday, May 9th, Suzanne Sawochka Hooper sold 2,500 shares of Jazz Pharmaceuticals PLC stock. The shares were sold at an average price of $160.00, for a total transaction of $400,000.00.
  • On Thursday, April 27th, Suzanne Sawochka Hooper sold 2,500 shares of Jazz Pharmaceuticals PLC stock. The shares were sold at an average price of $160.00, for a total transaction of $400,000.00.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded up 0.80% during mid-day trading on Friday, reaching $161.13. 417,151 shares of the company’s stock were exchanged. Jazz Pharmaceuticals PLC has a 12 month low of $95.80 and a 12 month high of $163.75. The stock has a 50-day moving average of $153.65 and a 200-day moving average of $142.97. The firm has a market cap of $9.67 billion, a price-to-earnings ratio of 24.35 and a beta of 1.11.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported $1.41 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.42 by $0.01. The company had revenue of $376.10 million during the quarter, compared to the consensus estimate of $376.58 million. Jazz Pharmaceuticals PLC had a net margin of 26.28% and a return on equity of 24.65%. Jazz Pharmaceuticals PLC’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the previous year, the company earned $2.26 EPS. Analysts anticipate that Jazz Pharmaceuticals PLC will post $11.01 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Suzanne Sawochka Hooper Sells 4,580 Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Stock” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/07/21/suzanne-sawochka-hooper-sells-4580-shares-of-jazz-pharmaceuticals-plc-nasdaqjazz-stock.html.

A number of research analysts have recently issued reports on the stock. Deutsche Bank AG set a $178.00 target price on shares of Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research note on Monday. Piper Jaffray Companies set a $182.00 target price on shares of Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research note on Friday, July 14th. Cowen and Company reiterated a “buy” rating and issued a $190.00 target price on shares of Jazz Pharmaceuticals PLC in a research note on Friday, July 14th. Mizuho cut shares of Jazz Pharmaceuticals PLC from a “buy” rating to a “neutral” rating and cut their target price for the company from $162.00 to $150.00 in a research note on Tuesday, July 4th. Finally, Leerink Swann lifted their target price on shares of Jazz Pharmaceuticals PLC from $169.00 to $170.00 and gave the company a “buy” rating in a research note on Tuesday, July 4th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $182.56.

Institutional investors have recently added to or reduced their stakes in the stock. OppenheimerFunds Inc. increased its position in Jazz Pharmaceuticals PLC by 54.1% in the first quarter. OppenheimerFunds Inc. now owns 150,840 shares of the specialty pharmaceutical company’s stock valued at $21,891,000 after buying an additional 52,960 shares during the last quarter. UBS Group AG increased its position in Jazz Pharmaceuticals PLC by 17.3% in the first quarter. UBS Group AG now owns 338,433 shares of the specialty pharmaceutical company’s stock valued at $49,116,000 after buying an additional 50,032 shares during the last quarter. Pinnacle Associates Ltd. acquired a new position in Jazz Pharmaceuticals PLC during the first quarter valued at about $235,000. TIAA CREF Investment Management LLC increased its position in Jazz Pharmaceuticals PLC by 178.2% in the first quarter. TIAA CREF Investment Management LLC now owns 663,548 shares of the specialty pharmaceutical company’s stock valued at $96,301,000 after buying an additional 425,042 shares during the last quarter. Finally, Sei Investments Co. increased its position in Jazz Pharmaceuticals PLC by 1,718.1% in the first quarter. Sei Investments Co. now owns 10,727 shares of the specialty pharmaceutical company’s stock valued at $1,557,000 after buying an additional 10,137 shares during the last quarter. 85.91% of the stock is owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Stock Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.